Related to this topic: Leaflets | Support | UK Guidelines | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Idiopathic Thrombocytopenic Purpura (ITP)

The term idiopathic thrombocytopenic purpura (ITP) describes an autoimmune disorder in which the number of circulating platelets is reduced due to their increased destruction.1
ITP is a diagnosis of exclusion and is heterogeneous in origin . Not truly understanding the aetiology, and the lack of clinical data from controlled prospective studies create controversies in both diagnosis and management.

Aetiology

Antibody binds to platelet antigens, resulting in a persistent thrombocytopenia. It is a condition which can occur in both adults and children, and can be acute or chronic in nature.
Immune thrombocytopenia may occasionally also occur in patients with pre-existing auto-immune diseases, eg systemic lupus erythematosus or in some malignant conditions.
Recent studies have found a high number of ITP patients with a positive family history, indicating the likely existence of a genetic susceptibility for ITP.2

ITP in children

ITP in children most commonly occurs following an infection, or occasionally following immunization.
It is usually a self limiting disorder which recovers spontaneously after 6-8 weeks. It can occur at any age, but children over the age of 10 may develop chronic ITP.

Epidemiology

The incidence of childhood ITP is of the order of 4.0-5.0 per 100,000, of which 15-20% will go on to develop the chronic form.3
It is more common in girls. Female:male 3:1

Symptoms and signs

Many children with ITP will have no symptoms at all, although some will develop purpura and bruising over a 48 hour period, and occasionally bleeding e.g. nose bleeds or gastrointestinal bleeds.
Intracranial bleeds occur very rarely.

Differential diagnosis

In infants hereditary thrombocytopenia must be considered, as must ITP in the mother.
In older children the differential diagnosis includes:

  • Aplastic anaemia
  • Leukaemia
  • Fanconi anaemia
  • von Willibrand's disease
  • Meningococcal septicaemia
  • Non-accidental injury.

Investigations

  • Full blood count
  • Platelet count
  • Bone marrow examination- only required if atypical features or diagnosis in doubt.

Management

Treatment is considered on the basis of clinical symptoms and not on the basis of platelet count alone, as children with severe thrombocytopenia are often asymptomatic and do not have a serious risk of a bleed.3Outcomes other than platelet count are important in children with ITP, most especially the severity of haemorrhage, cost and side effects of treatment, and overall quality of life.4
It has been observed that only around 17% of children with ITP have a major haemorrhage.5 Only a minority of these patients had an immediate rise in platelet count after receiving intravenous immunoglobulin, corticosteroid treatment, or both.

Non-drug

The majority of children with acute or chronic ITP will require only advice, support and repeat FBC 10 days after diagnosis to ensure that there is no generalised marrow disorder.
Further monitoring of the FBC is not required unless a change in the childs condition occurs to suggest that remission has occurred, or that deterioration has taken place.

Drugs

Any of the following may be used in a specialist setting if it is thought that the clinical condition requires that the platelet count should be raised:

  • Prednisolone
  • High dose methyl prednisolone
  • Pulsed dexamethasone
  • Intravenous immunoglobulin
  • Platelet transfusion
  • Anti-D immunoglobulin.

A recent cost-benefit analysis of these therapies found that the clinical benefit of anti-D was offset by a substantial cost increase.6 Although often overlooked in favour of newer agents, a brief course of high-dose prednisolone was an inexpensive and effective treatment for acute ITP.

Surgical

Splenectomy is rarely indicated in childhood ITP, and is only used in the event of life threatening bleeding, or in children with severe, chronic, unremitting ITP present for 12-24 months with severe symptoms.
It has been found that repeated doses of anti-D could maintain platelet count above the critical values, or double baseline counts in nearly two thirds of patients.7 This provides good control of bleeding and may serve as an alternative to splenectomy in some patients.

Prognosis

The vast majority of children have completely recovered within 6 months and will go on to have no further problems.
A small number will develop a chronic thrombocytopenia, but most of these will require no treatment.
The remainder will be treated as warranted by clinical condition.

Adult ITP

Unlike ITP in children, adult ITP does not normally follow an infection, and usually has an insidious onset.8

Epidemiology

It is predominantly a disease of women of childbearing age.
The incidence of chronic adult ITP is 5.8-6.6 per 100,000.

Signs and symptoms

As in children, adults with ITP may demonstrate a range of symptoms from none at all through to severe haemorrhage.

Investigations

  • FBC
  • Blood film
  • Auto-immune screen to exclude other auto-immune diseases
  • Platelet anti-body measurements
  • Bone marrow aspiration may be carried out if aged >60, or if atypical features.

Differential diagnosis

  • Aplastic anaemia
  • Effects of drugs or toxins on bone marrow, e.g. alcohol
  • Leukaemia
  • Von Willibrands disease
  • Marrow infiltration by secondary tumour.

Management

Adults with ITP, like children, will only require active management if their symptoms are severe enough to warrant it.
Treatment may also be used prophylactically to cover e.g. surgery.
Treatment would normally only be initiated in a specialist setting and might include:

  • Oral prednisolone
  • Pooled immunoglobulin
  • Splenectomy - more likely to result in lasting response in adults ( Patients post splenectomy should be vaccinated against Pneumococcus spp., Haemophilus spp. and Meningococcus spp. and should be issued with a course of broad spectrum antibiotics to use if they develop a fever, They should also be advised to purchase an alert bracelet).
  • Danazol
  • Immunosuppressive agents e.g. cyclosporin
  • Plasmapheresis
  • Numerous other agents are currently undergoing evaluation e.g.Rituximab and thrombopoietin (TPO)-like agents.9Management of patients with refractory ITP is difficult. Recent studies have shown that rituximab, a chimeric anti-CD20 monoclonal antibody, is useful in the treatment of these patients, with overall response rates of about 50%.10

Prognosis

The natural history of ITP in adults is very variable, the prognosis being dependent on the severity of the symptoms, and the response to any therapy.

Document references
  1. BCSH Guidelines; Management of ITP in Adults, children and in pregnancy. British Journal Haematology, 2003.
  2. Rischewski JR, Imbach P, Paulussen M, et al; Idiopathic thrombocytopenic purpura (ITP): Is there a genetic predisposition? Pediatr Blood Cancer. 2006 Oct 15;47 Suppl 5:678-80. [abstract]
  3. Lilleyman JS; Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol. 1999 Jun;105(4):871-5.
  4. Buchanan GR, Adix L; Current challenges in the management of children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer. 2006 Oct 15;47 Suppl 5:681-4. [abstract]
  5. Medeiros D, Buchanan GR; Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998 Sep;133(3):334-9. [abstract]
  6. O'Brien SH, Ritchey AK, Smith KJ; A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer. 2006 Mar 20. [abstract]
  7. El Alfy MS, Mokhtar GM, El-Laboudy MA, et al; Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol. 2006;115(1-2):46-52. [abstract]
  8. McMillan R; Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981 May 7;304(19):1135-47.
  9. Bussel J; Treatment of immune thrombocytopenic purpura in adults. Semin Hematol. 2006 Jul;43(3 Suppl 5):S3-10; discussion S18-9. [abstract]
  10. Braendstrup P, Bjerrum OW, Nielsen OJ, et al; Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005 Apr;78(4):275-80. [abstract]
Internet and further reading
  • Silverman MA; Idiopathic thrombocytopenic purpura. May, 2006.
Acknowledgements EMIS is grateful to Dr Hayley Willacy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2008.
DocID: 1562
Document Version: 21
DocRef: bgp24875
Last Updated: 24 Sep 2006
Review Date: 23 Sep 2008










Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>







Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>

PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page